Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Rhea-AI Summary
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorder treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The management team will deliver a presentation on Wednesday, December 4, 2024, at 2:30pm Eastern Time. The presentation will be accessible via live audio webcast through the investor relations section of Neuronetics' website at ir.neuronetics.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, STIM gained 6.26%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the “FDA”) for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When is Neuronetics (STIM) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Neuronetics' (STIM) presentation at the Piper Sandler Conference?
Which healthcare conference is Neuronetics (STIM) participating in December 2024?
